If You Invested in POLOMAR HEALTH SVCS INC (PMHS)

Polomar Health Services, Inc. (PMHS) is a Nevada corporation whose common stock is quoted on the OTC market under the symbol "PMHS," as disclosed in its registration statements on Form S-1 and S-1/A. According to these filings, the company operates through its subsidiary Polomar Specialty Pharmacy, LLC and focuses on pharmacy services that involve the preparation and dispensing of compounded medications.

Business overview

The S-1 prospectus summary states that Polomar Health Services, Inc. operates Polomar Specialty Pharmacy, LLC, a State of Florida licensed retail compounding pharmacy located in Palm Harbor, Florida. Polomar Specialty Pharmacy holds a Special Sterile Compounding Pharmacy permit, which authorizes it to dispense injectable and other sterile compounds, such as eye drops and infused therapeutics, upon receipt of a valid prescription. The compounding facility operates under the framework of Section 503A "Compounding Pharmacy" of the Federal Food, Drug and Cosmetic Act, which governs the manufacture of compounded drugs and fulfillment of prescriptions from licensed prescribers.

Based on the same S-1 disclosure, the company is authorized to fulfill and deliver compounded prescribed medications in multiple U.S. states and is engaged in seeking additional state-level approvals. The filings describe a focus on expanding the geographic scope of its pharmacy operations through licensing and regulatory authorizations.

Corporate structure and background

Polomar Health Services, Inc. is incorporated in the State of Nevada, with a Commission File Number of 000-56555 and an Internal Revenue Service Employer Identification Number of 86-1006313, as reported in its S-1 and S-1/A registration statements. The company’s filings explain that references to "Polomar" or the "Company" refer to Polomar Health Services, Inc., formerly known as Trustfeed Corp., and prior to that Healthmed Services Ltd. and Telemax Communications, together with its consolidated subsidiaries.

The NT 10-Q filing describes a significant corporate transaction: on June 28, 2024, the registrant (then named Trustfeed Corp.), through a wholly owned subsidiary, entered into an Agreement and Plan of Merger and Reorganization with Polomar Specialty Pharmacy, LLC. The merger and related transactions were consummated on September 30, 2024. The NT 10-Q states that the merger is accounted for as a "reverse recapitalization," with the historical financial statements of Polomar Specialty Pharmacy substituted for those of the registrant. Following this merger, the registrant ceased commercializing its prior business and began operating Polomar Specialty Pharmacy, a State of Florida licensed retail compounding pharmacy.

Compounding pharmacy activities

According to the S-1 prospectus summary, Polomar Specialty Pharmacy operates under Section 503A of the Federal Food, Drug and Cosmetic Act. This section authorizes a licensed compounding pharmacy to manufacture compounded drugs and fulfill prescriptions provided by licensed physicians, physician assistants and nurse practitioners. The filings state that, as a result of this regulatory framework and the company’s licensing status, Polomar is authorized to fulfill and deliver compounded prescribed medications in a specified number of states.

The same S-1 disclosure notes that Polomar Specialty Pharmacy is licensed as a Special Sterile Compounding Pharmacy, which permits it to dispense injectable and other sterile compounds when presented with valid prescriptions. This regulatory status is central to the company’s operations as described in its SEC registration materials.

Capital markets and registration activity

Polomar Health Services, Inc. has filed a registration statement on Form S-1 and subsequent amendments (S-1/A) under the Securities Act of 1933. These filings relate to the resale of shares of common stock by selling stockholders and describe the company as a smaller reporting company and non-accelerated filer. The S-1 and S-1/A specify that the common stock has a par value of $0.001 per share and is quoted on the OTC market under the symbol "PMHS." The registration statements indicate that the securities may be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act.

The S-1/A filed in December 2025 includes an explanatory note that it is being submitted to address comments from the Division of Corporation Finance and to include language under Rule 473(b) of the Securities Act. The registration materials emphasize that the preliminary prospectus is subject to completion and that the securities may not be sold until the registration statement becomes effective.

Material agreements and strategic transactions

In an 8-K filed in October 2025, Polomar Health Services, Inc. reports entering into a First Amendment to an Agreement and Plan of Merger and Reorganization dated July 23, 2025, with Polomar Merger Sub, Inc. and Altanine Inc. The amendment modifies the exchange ratio applicable to common and preferred stock in the contemplated merger. The 8-K notes that the summary of the amendment is qualified in its entirety by the full text of the agreement filed as an exhibit.

Another 8-K filed in December 2025 describes a Second Amendment to an Amended and Restated Product Fulfillment and Distribution Agreement with ForHumanity, Inc. and Island Group 40, LLC. According to this filing, the amendment adjusts exclusivity periods, provides for termination rights if certain minimum average monthly sales targets are not met over a specified period, and modifies conditions under which exclusivity can be extended based on revenue thresholds. It also revises the schedule for guaranteed payments due to the company and acknowledges receipt of a portion of those payments. The filing states that the summary is subject to and qualified by the full text of the Second Amendment, which is incorporated by reference as an exhibit.

Reporting status and financial reporting

Polomar Health Services, Inc. files periodic reports under the Securities Exchange Act of 1934. In a Form 12b-25 (NT 10-Q) filed in November 2025, the company notifies the SEC of a delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. The narrative section explains that the delay is primarily due to unexpected issues in completing the financial statements without unreasonable effort or expense. The company indicates that it is working to complete the Form 10-Q as soon as possible and expects to file within the time period permitted by Rule 12b-25.

The same NT 10-Q includes a discussion of revenues, operating expenses and net loss for the nine months ended September 30, 2025, compared with the prior-year period, and attributes changes in these figures to the company’s transition in business following the merger with Polomar Specialty Pharmacy and to legal, accounting, consulting, interest and payroll costs. These details are provided in the context of explaining anticipated changes in results of operations in the delayed quarterly report.

Regulatory framework and indemnification

The S-1/A registration statement describes the company’s incorporation under Nevada law and summarizes provisions of the Nevada Revised Statutes relating to indemnification of directors, officers, employees and agents. It explains that, under NRS Sections 78.7502 and 78.747, the company may indemnify such persons for expenses, judgments, fines and settlement amounts under specified conditions, and that its bylaws provide for indemnification to the fullest extent permitted by Nevada law. The filing also notes that the company may purchase and maintain insurance on behalf of directors and officers and that it maintains director and officer liability insurance.

Historical names and evolution

According to the S-1 and S-1/A, Polomar Health Services, Inc. has undergone several name changes over its corporate history. The filings state that the company is a Nevada corporation formerly known as Trustfeed Corp., and prior to that as Healthmed Services Ltd. and Telemax Communications. The NT 10-Q further explains that, as a result of the merger with Polomar Specialty Pharmacy, the registrant ceased commercializing its pre-merger business and now operates the compounding pharmacy business.